Clinical Trial Recruiting Mesothelioma Patients to Undergo Immunotherapy Treatment MesoPher

MHN Staff

Amphera, a Dutch biotechnology company has been developing a new immunotherapy for pleural mesothelioma—MesoPher. In March 2019, the company announced they have recruited the first patients to participate in their Phase 2/3 study to investigate MesoPher as a second-line treatment option for pleural mesothelioma. Currently, chemotherapy using a mixture of Alimta® (pemetrexed) and cisplatin drugs